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Abstract
Background: Morbidity due to schistosomiasis is currently controlled by treatment of schistosome infected people with the
antihelminthic drug praziquantel (PZQ). Children aged up to 5 years are currently excluded from schistosome control
programmes largely due to the lack of PZQ safety data in this age group. This study investigated the safety and efficacy of
PZQ treatment in such children.
Methods: Zimbabwean children aged 1–5 years (n = 104) were treated with PZQ tablets and side effects were assessed by
questionnaire administered to their caregivers within 24 hours of taking PZQ. Treatment efficacy was determined 6 weeks
after PZQ administration through schistosome egg counts in urine. The change in infection levels in the children 1–5 years
old (n = 100) was compared to that in 6–10 year old children (n = 435).
Principal Findings: Pre-treatment S. haematobium infection intensity in 1–5 year olds was 14.6 eggs/10 ml urine and
prevalence was 21%. Of the 104 children, 3.8% reported side effects within 24 hours of taking PZQ treatment. These were
stomach ache, loss of appetite, lethargy and inflammation of the face and body. PZQ treatment significantly reduced
schistosome infection levels in 1–5 year olds with an egg reduction rate (ERR) of 99% and cure rate (CR) of 92%. This was
comparable to the efficacy of praziquantel in 6–10 year olds where ERR was 96% and CR was 67%.
Interpretation/Significance: PZQ treatment is as safe and efficacious in children aged 1–5 years as it is in older children
aged 6–10 years in whom PZQ is the drug of choice for control of schistosome infections.
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Introduction
Classified among the neglected tropical diseases, urogenital
schistosomiasis (bilharzia), remains one of the most prevalent
parasitic diseases in the tropical and subtropical countries,
constituting a major public health problem. The disease is caused
by the helminth parasite Schistosoma haematobium and is the most
prevalent form of schistosomiasis in Africa and the Middle East
affecting approximately 107 million people. In affected popula-
tions, children carry the heaviest burden of infection [1,2]n and in
young children, urogenital schistosomiasis causes haematuria,
dysurea, nutritional deficiencies, anaemia, growth retardation,
decreased physical performance and impaired memory and
cognition [3,4,5,6,7].
Control of schistosome infections is through treatment of infected
people with a single dose of the anti-helminth drug praziquantel
which is safe, highly efficacious, cheap (costing less than US$0.50/
dose) and can reverse schistosome-related morbidity particularly in
the early stages of disease progression [8]. Current schistosome
control programmes advocated by the World Health Assembly in
2001 through resolution 54?19’s recommend regular de-worming of
school aged children at risk of infection (http://www.who.int/infpr-
2001/en/pr2001WHA-6.html), but exclude pre-school children i.e.
children aged 5 years and below due to the belief that these children
are not sufficiently exposed to infective water to experience high
infection rates [9] which would lead to the clinical manifestation of
disease and the lack of safety data on praziquantel in this age group
[10]. However, several studies have now shown prevalent
schistosome infection (as much as 100% in some areas) and
morbidity of African children below the age of 5 [11,12,13,14].
Thus these children are both at risk of infection and a potential
reservoir for the parasite in communities successfully targeted by
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mass anti-helminthic treatment. These findings have led to a
growing number of calls to include pre-school children and infants
in schistosome-control programmes [9,11,13,15]. We have previ-
ously assessed the side effects reported following PZQ treatment of
Zimbabwean school children exposed to S. haematobium aged 6 years
and above [16]. However, there have not been any studies on the
safety of PZQ treatment of S. haematobium infections in children
aged below 5 years of age. Furthermore, given that PZQ works
synergistically with the host immune system to kill the worms, the
efficacy of the drug in young children whose immune system might
differ from older children may be lower. Therefore the present study
assesses the safety of PZQ- treatment in 1–5 year old children in
Zimbabwe naturally exposed to S. haematobium infection. It also
compares efficacy rates in the 1–5 year old to those in 6–10 year old
children testing the hypotheses that (1) PZQ treatment reduces
infection levels and (2) PZQ efficacy rates in 1–5 year olds are
similar to those in 6–10 year olds.
Materials and Methods
Study area and population
The study was conducted in 3 villages, Magaya, Chipinda and
Chitate, in the Mashonaland East Province of Zimbabwe
(31u309E; 17u459S) where S. haematobium is endemic. Similar to
other rural areas in Zimbabwe, there is a low prevalence of
Schistosoma mansoni and soil transmitted helminths in this region
[2,17,18]. There had not been any schistosome control or research
programmes in the villages prior to this study. The participants are
involved in ongoing studies on the control and immuno-
epidemiology of human schistosomiasis. The main activity in
these villages is subsistence farming and human water contact is
frequent with at least 4 contacts/person/week (assessed by
questionnaire) due to insufficient safe water and sanitation
facilities. The questionnaire studies also confirmed that older
children are exposed to infective water actively while younger
children are also exposed passively when accompanying parents to
river sites or through river water bought back home [9] as indicted
by questionnaire responses of their parents/guardians.
Ethical statement
Permission to conduct the study in the region was obtained from
the Provincial Medical Director. Institutional and ethical approval
was received from the University of Zimbabwe and the Medical
Research Council of Zimbabwe respectively. In addition, the study
received ethical approval from the World Health Organization’s
Research Ethics Review Committee. At the beginning of the
study, parents and guardians of participating children had the
aims and procedures of the project explained fully in the local
language, Shona, and written consent was obtained from
participants’ parents/guardians before enrolment into the study.
After collection of all samples, all compliant participants (children
under 5 years of age, older children (6 years and above) and all
parents/guardians) were offered anti-helminthic treatment with
the recommended dose of praziquantel (40 mg/kg of body
weight).
Case-history questionnaires
At enrolment into the study, the parents/guardians of the
children (1–5 years old) were asked 30 questions on behalf of the
child recording demographic information, general socio-economic
indicators, access to health care, general self-reported health
conditions, water contact behaviours and general awareness and
knowledge on schistosome infection. Questionnaires were admin-
istered in Shona by a trained team member. The questionnaire
responses on the current health status of the child and the clinical
assessment of the nursing staff informed on the suitability of the
child to partake in the study.
Sample collection, PZQ treatment and assessment of side
effects
Stool and urine specimens were collected from each participant
on 3 consecutive days and processed using microscopic examination
of urine samples for S. haematobium following urine filtration [19],
and microscopic examination of stool samples for S. mansoni and
geo-helminths following the Kato Katz technique [20]. The formol-
ether concentration method was performed as previously described
[2,21] on a random sample of 25% of the stool samples to confirm
results obtained by the Kato-Katz technique. For infants, samples
were collected overnight if it was not possible to collect a sample on
the spot. After collection of the parasitology samples, participants
(children and their guardians/parents) were offered treatment with
the standard dose of praziquantel, i.e. 40 mg/kg body weight. Dose
was determined for all children by weighing and the weight measure
was rounded off to the nearest kg to determine the dose for each
child and where necessary, tablets were broken in half or quarters to
make up the appropriate dose. Irrespective of infection status, all
compliant participants (parents/guardians and children) were
treated with praziquantel tablets obtained from the IDA Founda-
tion (http://www.idafoundation.org/, catalogue number 13200;
6600 mg/tablet). This was in keeping with mass drug administra-
tion practices during the investigative epidemiological surveys. For
children aged 5 years and below, tablets were crushed using spoons
and administered by the parent/guardian under supervision of one
of the research teams. The tablets were taken with juice.
Acceptability of the tablet was assessed directly during PZQ drug
administration. A child would be recorded as not accepting drug
administration if he/she spat, choked or vomited the drug. All
treated people were given bread to eat after antihelminthic
treatment. Parents/guardians were encouraged to remain at the
treatment centre for 1 hour after administering the medication to
assess if the PZQ treatment had immediate side effects and to
determine whether the medication was lost through vomiting by the
Author Summary
Urogenital schistosomiasis is an important, but neglected,
infectious disease affecting over 100 million people, mainly
in Africa. Children carry the heaviest burden of infection
with children as young as 1 year old showing signs of
infection. Children aged 5 years and below are currently
excluded from schistosome control programmes for
several reasons, including operational difficulties associat-
ed with accessing preschool children, misconceptions
about their level of exposure to infective water and lack
of safety data on the drug of choice for schistosome
control, praziquantel, in children aged 5 years and below.
This study was one of a small number of studies recently
funded by the World Health Organization to investigate
the need for praziquantel treatment in preschool children
(aged 1–5 years) and to subsequently assess the safety and
efficacy of the drug praziquantel in this age group. This
study confirmed that preschool children carry significant
levels of schistosome infection, exceeding those carried by
their parents/guardians, highlighting the urgent need for
their immediate inclusion in schistosome control pro-
grammes. The study also showed that praziquantel
treatment is as safe and efficacious in children aged 1–5
years as it is in older children aged 6–10 years who are
currently the target for mass drug administration.
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participants. Parents/guardians reported back 24 hours after PZQ
treatment (preferably with the child) to answer a questionnaire with
9 questions on side effects following PZQ administration (i.e. not
present when PZQ was initially administered). Participants who
would not accept treatment on religious grounds or were absent
from school on treatment days but wished to remain part of the
study cohort effectively became untreated controls.
Inclusion and exclusion criteria
In order to be included in the PZQ safety study, participants
had to meet all the following criteria: 1) be aged 1–5 years at
recruitment, 2) had been resident in the study area since birth, 3)
had provided at least two urine and two stool samples on
consecutive days, 4) be negative for intestinal helminths and S.
mansoni (no one was excluded on this criteria as everyone was
negative for these infections as is reported in other parts of
Zimbabwe [22]), 5) have successfully taken the PZQ tablets
prescribed to them and, 6) parents/guardians had provided
answers to the 24 hour post-treatment side effects questionnaire.
104 participants met these criteria and were included in the PZQ
safety study. To be included in the treatment efficacy study, the
children had to meet criteria 2–4 above. In addition they had to
have been offered PZQ treatment if present on treatment days and
had provided at least 2 urine and 2 stool samples on consecutive
days, 6 weeks after treatment with PZQ. For both studies, children
were excluded if the parents/guardians/the child themselves (in
the case of older children) reported a pre-existing illness or if they
were suffering from a fever as assessed by clinical examination by
the nursing staff. 100 children aged 1–5 years of age met this
criteria (72 treated with PZQ, 28 untreated) and 435 children aged
6–10 years old (355 treated with PZQ and 80 untreated). The
larger sample size of 6–10 year olds reflects the school-based
recruitment design of the study.
Statistical analysis
Statistical tests using the statistical package in PASW (formerly
SPSS) were used to test two hypotheses (1) PZQ treatment
significantly reduces infection levels and (2) PZQ efficacy rates in
1–5 year olds are similar to those in 6–10 year olds. The effect of
treatment on infection prevalence levels for the whole study
group was tested using a logistic regression approach with
variables selected using the forward stepwise conditional method
[23]. The dependent variable was infection status 6 weeks after
treatment (infected vs. uninfected) while the independent
variables were pre-treatment infection intensity (log10(x+1)
transformed), sex (male vs. female), age group (group 1 (1–5
years old) vs. group 2 (6–10 years old)), treatment status (PZQ
treated vs. untreated) and the interaction between age group and
treatment status. The model passed the Hosmer and Lemenshaw
goodness of fit of the test [23]. Infection prevalences between age
groups and infection status were compared using a one-tailed chi-
squared test with 95% CI calculated using a Binomial
distribution.
Infection intensity was compared using repeated measures
ANOVA. For this analysis, the dependent variable infection
intensity was log10(x+1) transformed, the independent variables
which were all categorical were sex (male, female) age group (two
groups, group 1= 1–5 years, group 2=6–10 years), treatment
(1 = untreated, 2 =PZQ treated). Potential confounding effects of
sex and village were allowed for by using sequential sums of
squares with these two variables entered first and second in the
model. The interaction between age-group and treatment was also
tested to determine if the effect of treatment varied depending on
age group. Test statistics were taken as significant at p#0.05. Post-
hoc paired T-tests were conducted to determine differences in
infection levels between the time points (pre-treatment vs. 6 weeks
post-treatment).
Results
Study area infection intensity
The children came from 3 villages endemic for S. haematobium
infection; an initial survey of 1980 permanent residents of the
study villages aged 1–80 years showed an overall infection
prevalence of 30.5% and arithmetic mean infection intensity of
21.1 eggs/10 ml urine (SEM=1.9 and range 0–1000 eggs/10 ml
urine). Infection prevalence and intensity followed a convex age-
infection profile with infection levels rising to peak in people aged
11 to 20 years old and infection intensity declining faster than
infection prevalence thereafter (Figures 1 and 2). Schistosome
infection levels in 1–5 year olds in the population were higher than
in adults aged 21 years and above.
Safety of PZQ in 1–5 year olds
PZQ drug dose was determined by weight which ranged from
8 kg to 24 kg in the 1–5 year olds (mean 16.7 kg, standard error of
the mean= 0.46). During PZQ administration, there was only one
record of failure to accept the drug, where the child vomited the
tablets. There were no other side-effects directly related to tablet
administration. 104 children were treated with PZQ and their
parents completed side effects questionnaires 24 hours after the
successful administration of PZQ tablets. S. haematobium eggs were
detected in urine samples from 15 of these children. Side effects
arising within 24 hours of treatment were reported in 4 children
aged 3–5 years old, none egg positive for S. haematobium infection.
The side effects reported were diarrhoea (3 children), lethargy (2
children), inflammation of the body and face (1 child, this has
subsided by bedtime and was confirmed resolved by the nursing
staff at the 24 hour examination), and loss of appetite (1 child).
Treatment efficacy
535 children were followed-up at the two time points to
determine the efficacy of PZQ treatment 6 weeks post treatment
and test whether PZQ efficacy was age-dependent. Pre-treatment
schistosome infection levels are shown in Table 1 by age group
and by treatment status. A more detailed breakdown of pre-
treatment infection distribution in the 100 children aged 1–5 years
is given in Table 2. There was a significant reduction in S.
haematobium infection intensity in children receiving PZQ treatment
compared to untreated children in both age groups (F = 15.165,
df = 1,528, p,0.001) as shown in Figure 3. In treated 1–5 year
olds, infection intensity declined from a mean of 9.9 to 0.1 eggs/
10 ml urine, giving an egg reduction rate of 99%. In untreated
children, mean infection intensity increased from 26.8 to 32.0
eggs/10 ml urine, with an egg reduction rate of 19%. In treated 6–
10 year olds, infection intensity declined from 27.0 to 1.1 eggs/
10 ml urine (egg reduction rate = 96%) compared to the change in
infection intensity in untreated children from 14.1 to 11.6 eggs/
10 ml urine (egg reduction rate = 19%). The statistical analyses
also showed that there was no significant interaction between
treatment and age group (F = 0.563, df = 1,528, p = 0.45) indicat-
ing that there was no significant difference in the efficacy of PZQ
treatment in 1–5 year olds compared to 6–10 year olds.
Infection prevalence followed similar patterns with prevalences
in treated children in both age groups declining significantly
compared to untreated children in both age groups (Wald = 5.68,
df = 1, p = 0.017) (Figure 4). In untreated children prevalences
declined from 28.5% to 17.9% in 1–5 year olds (x2= 0.90, df = 1,
Praziquantel Safety and Efficacy in Young Children
www.plosntds.org 3 May 2011 | Volume 5 | Issue 5 | e1143
p= 0.34) and 17.5% to16.5% in 6–10 year olds (x2= 0.05, df = 1,
p = 0.83), giving cure rates of 38% and 7% respectively. In treated
children prevalences fell from 18.0% to 1.4% in 1–5 year olds
(x2= 11.4, df = 1, p = 0.001) and 38.0% to 11.8% in 6–10 year
olds (x2= 65,1, df = 1, p,0.001) giving cure rates of 92% and
67% respectively. This difference in cure rates in treated children
was not statistically significantly different between the age groups
as the interaction between treatment and age-group was not
significant.
Discussion
Despite the public health prominence of schistosomiasis in
Africa and the availability of a cheap and efficacious drug to treat
infected people, fewer than 5% of the infected population is
receiving treatment [10]. Included in the group of affected people
currently not receiving treatment, are children aged 5 years and
below. Current mass drug administration (MDA) schistosome
control programmes exclude children aged 5 years and below for
Figure 1. Schistosoma haematobium infection intensity in the study villages. Arithmetic mean of schistosome infection intensity for each age
group. Bars represent standard error of the mean.
doi:10.1371/journal.pntd.0001143.g001
Figure 2. Schistosoma haematobium infection prevalence in the study villages. Infection prevalence for each age group. Bars represent 95%
CI.
doi:10.1371/journal.pntd.0001143.g002
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several reasons including (1) practicality; mass helminth control
programmes in Africa are largely school based so as to take
advantage of existing infrastructure serving an accessible popula-
tion. These children tend to be aged 6 years and above which
means non-enrolled children below the age of 6 are excluded from
such programmes; (2) misconceptions about the levels of infection
in this age group and (3) lack of safety data in this age group. This
study showed that children aged 5 years and below carry infection
levels higher than those of their parents/guardians i.e. people aged
21 and above, who are currently eligible for inclusion in MDA
programmes). Furthermore, whilst it is known that schistosome
infection intensity and morbidity are aggregated in school
children, current estimates predict that pre-school children, who
are relatively under-represented in field studies, also bear a
significant urogenital disease burden in sub-Saharan Africa [24]
Therefore, based on infection levels in these children the present
study adds field data to support the growing calls for inclusion of
children under 5 in schistosome control programmes [9,11,13,15].
Although PZQ can be prescribed on a case-by-case basis in
young children, there have not been studies on the safety of PZQ
treatment of S. haematobium infection in children under 5 years of
age with a view to include them in MDA programmes. In this
study four out of 104 children (3.8%) reported mild side effects
(headache, loss of appetite, stomach ache and general weakness)
occurring within 24 hours after taking praziquantel tablets which
is less than what we have reported in older (primary school)
children [16] and that reported from S. mansoni studies in endemic
[25] and epidemic [26] areas. There are likely to be biases in
parent/guardian reporting side effects on behalf of the child, but
this approach has recently been used successfully in studies of the
safety of PZQ treatment in 0–5 year olds exposed to S. mansoni
infections which reported higher percentages of side effects than
those reported in the present study. The low percentage of
children suffering side effects in the present study may be related to
the low levels of infection they were carrying since previous studies
show that the frequency and severity of side effects is proportional
to the intensity of schistosome infection [25,26]. Both the safety
and efficacy studies presented here included egg negative and egg
positive children since microscopic examination of urine and stool
samples for parasite eggs are currently the ‘gold’ standard field
method of diagnosing schistosome infections, but the procedures
can miss light, single sex or pre-patent infections. The lower
levels of side effects reported here compared to those reported in
S. mansoni infections may also be related to differences between the
parasites. Olds et al reported different levels of PZQ- related side
effects between children infected with S. mansoni and S. haematobium
[27].
PZQ treatment was efficacious, significantly reducing infection
intensity and prevalence in treated children compared to
untreated children. There were changes in infection levels in the
untreated group of children in the 6 weeks between the
recruitment and efficacy check surveys possibly reflecting both
transmission related changes in infection levels as well as
inaccuracies in the diagnosis. A number of studies have
demonstrated that the schistosomicidal effect of praziquantel
depends upon the immune status of the host [28,29]. Our previous
studies and those of others have indicated that acquired immunity
against schistosomes develops slowly over several years
Table 1. Distribution of infection intensity and prevalence in both age groups (1–5 years old) and (6–10 years old) in the study
population.
Age (years) PZQ infection status Sample size
Mean infection
intensity* SEM**
Min infection
intensity
Max infection
intensity
Infection prevalence
(%)
1–5 Untreated 28 26.8 16.1 0 380 29
PZQ–treated 72 9.9 6.4 0 458 18
Total 100 14.6 6.5 0 458 21
6–10 Untreated 80 14.4 7.1 0 502 18
PZQ–treated 355 27.0 4.8 0 878 38
Total 435 24.7 4.1 0 878 34
Total Untreated 108 17.6 6.7 0 502 20
PZQ–treated 427 24.1 4.1 0 878 35
Total 535 22.8 3.6 0 878 32
*Arithmetic mean, units = eggs/10 ml urine;
**Standard Error of the Mean.
doi:10.1371/journal.pntd.0001143.t001
Table 2. Distribution of infection intensity and prevalence in 1–5 year old children in the study population.
Age (years) Sample size Mean infection intensity* SEM** Infection prevalence (%)
1.0–3 13 0.2 0.2 8
3.1–4 24 22.4 19.1 17
4.1–5 63 14.7 7.3 25
Total 100 14.6 6.5 21
*Arithmetic mean, units = eggs/10 ml urine;
**Standard Error of the Mean.
doi:10.1371/journal.pntd.0001143.t002
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Figure 4. Praziquantel efficacy in reducing infection prevalence in different age groups. Comparison of PZQ treatment between 1–5 year
old children vs. 6–10 year old children. Infection prevalence before treatment is shown in black and those 6 weeks after treatment are shown in white.
Bars represent 95% CI. Test-statistic values are from x2 tests.
doi:10.1371/journal.pntd.0001143.g004
Figure 3. Praziquantel efficacy in reducing infection intensity in different age groups. Comparison of treatment efficacy in 1–5 year old
children vs. 6–10 year old children. Infection intensity before treatment is shown in black and those 6 weeks after treatment are shown in white Bars
represent standard error of the mean. Test-statistic values are from paired T tests.
doi:10.1371/journal.pntd.0001143.g003
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[30,31,32,33,34,35,36,37,38]. Such results have often been taken as
an indication that the immune responses of very young children
may not have developed sufficiently to provide the synergy required
for efficient praziquantel action. Therefore, PZQ treatment efficacy
rates were compared between 1–5 year old children and 6–10 year
old children. The egg reduction rates of 99% and 96% respectively
were comparable between the two age groups while the cure rate of
92% in 1–5 year olds was higher than the 67% in 6–10 year olds,
although this difference was not statistically significant.. Thus, the
present results do not support the suggestion that the immune
system in 1–5 year olds is not sufficiently developed to act
synergistically with praziquantel rather, the results indicate that
these children can be successfully cured of schistosome infections
and argues for their inclusion in schistosome control programmes
both to reduce schistosome infection and to induce earlier
expression of protective responses which may help reduce morbidity
in later life [34,39]. The higher cure rates in the 1–5 year olds are
likely to be related to the lower levels of infection they were carrying
compared to the older children, an observation we have previously
reported in older children [16] although the possibility of early re-
infection in the older children which would mask cure rates, cannot
be entirely ruled out.Both ERR and CR were within the values we
and others have previously reported for S. haematobium infections
[16,40,41,42].
Taken together, the present study found that S. haematobium
infection levels in 1–5 year olds exceeded those in adults aged 21
and above. Side effects following administration of PZQ were low
suggesting that PZQ treatment was safe in the 1–5 year old
children. PZQ treatment was also efficacious in this age group
reducing infection levels and treatment efficacy was comparable to
that in 6–10 year olds.
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